| COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study MC Garassino, JG Whisenant, LC Huang, A Trama, V Torri, F Agustoni, ... The Lancet Oncology 21 (7), 914-922, 2020 | 647 | 2020 |
| Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional … B Ricciuti, C Genova, A De Giglio, M Bassanelli, MG Dal Bello, G Metro, ... Journal of cancer research and clinical oncology 145, 479-485, 2019 | 290 | 2019 |
| PD/1-PD-Ls checkpoint: insight on the potential role of NK cells S Pesce, M Greppi, F Grossi, G Del Zotto, L Moretta, S Sivori, C Genova, ... Frontiers in immunology 10, 464453, 2019 | 174 | 2019 |
| The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients MG Dal Bello, RA Filiberti, A Alama, AM Orengo, M Mussap, S Coco, ... Journal of translational medicine 17, 1-10, 2019 | 141 | 2019 |
| Therapeutic implications of tumor microenvironment in lung cancer: focus on immune checkpoint blockade C Genova, C Dellepiane, P Carrega, S Sommariva, G Ferlazzo, ... Frontiers in immunology 12, 799455, 2022 | 116 | 2022 |
| Liquid biopsy in non-small cell lung cancer: highlights and challenges E Rijavec, S Coco, C Genova, G Rossi, L Longo, F Grossi Cancers 12 (1), 17, 2019 | 107 | 2019 |
| Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab … A Cortellini, M Di Maio, O Nigro, A Leonetti, DL Cortinovis, JGJV Aerts, ... Journal for immunotherapy of cancer 9 (4), 2021 | 94 | 2021 |
| Clinical applications of circulating tumor cells in lung cancer patients by CellSearch system A Truini, A Alama, MG Dal Bello, S Coco, I Vanni, E Rijavec, C Genova, ... Frontiers in oncology 4, 242, 2014 | 89 | 2014 |
| Clinical outcomes and toxic effects of single-agent immune checkpoint inhibitors among patients aged 80 years or older with cancer: a multicenter international cohort study CA Nebhan, A Cortellini, W Ma, T Ganta, H Song, F Ye, R Irlmeier, ... JAMA oncology 7 (12), 1856-1861, 2021 | 85 | 2021 |
| Harnessing NK cells for cancer treatment P Minetto, F Guolo, S Pesce, M Greppi, V Obino, E Ferretti, S Sivori, ... Frontiers in immunology 10, 2836, 2019 | 84 | 2019 |
| Correlation of PD-L1 expression with tumor mutation burden and gene signatures for prognosis in early-stage squamous cell lung carcinoma H Yu, Z Chen, KV Ballman, MA Watson, R Govindan, I Lanc, DG Beer, ... Journal of Thoracic Oncology 14 (1), 25-36, 2019 | 84 | 2019 |
| Serial troponin for early detection of nivolumab cardiotoxicity in advanced non‐small cell lung cancer patients M Sarocchi, F Grossi, E Arboscello, A Bellodi, C Genova, MG Dal Bello, ... The oncologist 23 (8), 936-942, 2018 | 84 | 2018 |
| Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression≥ 50%: a multicenter study with external validation A Cortellini, B Ricciuti, M Tiseo, E Bria, GL Banna, JGJV Aerts, F Barbieri, ... Journal for immunotherapy of cancer 8 (2), 2020 | 75 | 2020 |
| Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of≥ 50% A Cortellini, M Tiseo, GL Banna, F Cappuzzo, JGJV Aerts, F Barbieri, ... Cancer Immunology, Immunotherapy 69, 2209-2221, 2020 | 69 | 2020 |
| Thoracic Cancers International COVID-19 Collaboration (TERAVOLT): Impact of type of cancer therapy and COVID therapy on survival. L Horn, JG Whisenant, V Torri, LC Huang, A Trama, LG Paz-Ares, E Felip, ... Journal of Clinical Oncology 38 (18_suppl), LBA111-LBA111, 2020 | 66 | 2020 |
| Association between response to nivolumab treatment and peripheral blood lymphocyte subsets in patients with non-small cell lung cancer S Ottonello, C Genova, I Cossu, V Fontana, E Rijavec, G Rossi, F Biello, ... Frontiers in immunology 11, 125, 2020 | 65 | 2020 |
| Radiomic detection of EGFR mutations in NSCLC G Rossi, E Barabino, A Fedeli, G Ficarra, S Coco, A Russo, V Adamo, ... Cancer Research 81 (3), 724-731, 2021 | 63 | 2021 |
| Real-life results from the overall population and key subgroups within the Italian cohort of nivolumab expanded access program in non-squamous non–small cell lung cancer F Grossi, C Genova, L Crinò, A Delmonte, D Turci, D Signorelli, A Passaro, ... European Journal of Cancer 123, 72-80, 2019 | 62 | 2019 |
| Immune-related adverse events of pembrolizumab in a large real-world cohort of patients with NSCLC with a PD-L1 expression≥ 50% and their relationship with clinical outcomes A Cortellini, A Friedlaender, GL Banna, G Porzio, M Bersanelli, ... Clinical lung cancer 21 (6), 498-508. e2, 2020 | 60 | 2020 |
| Next generation sequencing in non-small cell lung cancer: new avenues toward the personalized medicine S Coco, A Truini, I Vanni, M Giovanna Dal Bello, A Alama, E Rijavec, ... Current drug targets 16 (1), 47-59, 2015 | 60 | 2015 |
